BACKGROUND: Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or specificity. DESIGN AND METHODS: We examined the potential of gene expression profiles to classify pediatric acute myeloid leukemia. Gene expression microarray data of 237 children with acute myeloid leukemia were collected and a double-loop cross validation approach was used to generate a subtype-predictive gene expression profile in the discovery cohort (n=157) which was then tested for its true predictive value in the independent validation cohort (n=80). The classifier consisted of 75 probe sets, representing the top 15 discriminating probe sets for MLL-rearranged, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive acute myeloid leukemia. RESULTS: These cytogenetic subtypes represent approximately 40% of cases of pediatric acute myeloid leukemia and were predicted with 92% and 99% accuracy in the discovery and independent validation cohort, respectively. However, for NPM1, CEBPA, MLL(-PTD), FLT3(-ITD), KIT, PTPN11 and N/K-RAS gene expression signatures had limited predictive value. This may be caused by a limited frequency of these mutations and by underlying cytogenetics. This latter is exemplified by the fact that different gene expression signatures were discovered for FLT3-ITD in patients with normal cytogenetics and in those with t(15;17)(q21;q22)-positive acute myeloid leukemia, which pointed to HOXB-upregulation being specific for FLT3-ITD(+) cytogenetically normal acute myeloid leukemia. CONCLUSIONS: In conclusion, gene expression profiling correctly predicted the most prevalent cytogenetic subtypes of pediatric acute myeloid leukemia with high accuracy. In clinical practice, this gene expression signature may replace multiple diagnostic tests for approximately 40% of pediatric acute myeloid leukemia cases whereas only for the remaining cases (predicted as 'acute myeloid leukemia-other') are additional tests indicated. Moreover, the discriminative genes reveal new insights into the biology of acute myeloid leukemia subtypes that warrants follow-up as potential targets for new therapies.
BACKGROUND:Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or specificity. DESIGN AND METHODS: We examined the potential of gene expression profiles to classify pediatric acute myeloid leukemia. Gene expression microarray data of 237 children with acute myeloid leukemia were collected and a double-loop cross validation approach was used to generate a subtype-predictive gene expression profile in the discovery cohort (n=157) which was then tested for its true predictive value in the independent validation cohort (n=80). The classifier consisted of 75 probe sets, representing the top 15 discriminating probe sets for MLL-rearranged, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive acute myeloid leukemia. RESULTS: These cytogenetic subtypes represent approximately 40% of cases of pediatric acute myeloid leukemia and were predicted with 92% and 99% accuracy in the discovery and independent validation cohort, respectively. However, for NPM1, CEBPA, MLL(-PTD), FLT3(-ITD), KIT, PTPN11 and N/K-RAS gene expression signatures had limited predictive value. This may be caused by a limited frequency of these mutations and by underlying cytogenetics. This latter is exemplified by the fact that different gene expression signatures were discovered for FLT3-ITD in patients with normal cytogenetics and in those with t(15;17)(q21;q22)-positive acute myeloid leukemia, which pointed to HOXB-upregulation being specific for FLT3-ITD(+) cytogenetically normal acute myeloid leukemia. CONCLUSIONS: In conclusion, gene expression profiling correctly predicted the most prevalent cytogenetic subtypes of pediatric acute myeloid leukemia with high accuracy. In clinical practice, this gene expression signature may replace multiple diagnostic tests for approximately 40% of pediatric acute myeloid leukemia cases whereas only for the remaining cases (predicted as 'acute myeloid leukemia-other') are additional tests indicated. Moreover, the discriminative genes reveal new insights into the biology of acute myeloid leukemia subtypes that warrants follow-up as potential targets for new therapies.
Authors: A von Bergh; B Emanuel; S van Zelderen-Bhola; T Smetsers; R van Soest; M Stul; H Vranckx; E Schuuring; A Hagemeijer; P Kluin Journal: Genes Chromosomes Cancer Date: 2000-05 Impact factor: 5.006
Authors: Brian V Balgobind; Iris H I M Hollink; Dirk Reinhardt; Elisabeth R van Wering; Siebold S N de Graaf; Andre Baruchel; Jan Stary; H Berna Beverloo; Georgine E de Greef; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink Journal: Eur J Cancer Date: 2010-03-16 Impact factor: 9.162
Authors: Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: Claus Meyer; Bjoern Schneider; Martin Reichel; Sieglinde Angermueller; Sabine Strehl; Susanne Schnittger; Claudia Schoch; Mieke W J C Jansen; Jacques J van Dongen; Rob Pieters; Oskar A Haas; Theo Dingermann; Thomas Klingebiel; Rolf Marschalek Journal: Proc Natl Acad Sci U S A Date: 2004-12-30 Impact factor: 11.205
Authors: Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Joost Meijer; Susanna van Oosterhoud; Wim L J van Putten; Peter J M Valk; H Berna Beverloo; Daniel G Tenen; Bob Löwenberg; Ruud Delwel Journal: Hematol J Date: 2003
Authors: Klaus H Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria-Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander Journal: J Clin Oncol Date: 2009-09-14 Impact factor: 44.544
Authors: Mary E Ross; Rami Mahfouz; Mihaela Onciu; Hsi-Che Liu; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Stanley Pounds; Cheng Cheng; Jing Ma; Raul C Ribeiro; Jeffrey E Rubnitz; Kevin Girtman; W Kent Williams; Susana C Raimondi; Der-Cherng Liang; Lee-Yung Shih; Ching-Hon Pui; James R Downing Journal: Blood Date: 2004-06-29 Impact factor: 22.113
Authors: Hetty H Helsmoortel; Barbara De Moerloose; Tim Pieters; Farzaneh Ghazavi; Silvia Bresolin; Hélène Cavé; Andrica de Vries; Valerie de Haas; Christian Flotho; Veerle Labarque; Charlotte Niemeyer; Pascale De Paepe; Nadine Van Roy; Jan Stary; Marry M van den Heuvel-Eibrink; Yves Benoit; Johannes Schulte; Steven Goossens; Geert Berx; Jody J Haigh; Frank Speleman; Pieter Van Vlierberghe; Tim Lammens Journal: Haematologica Date: 2016-03-11 Impact factor: 9.941
Authors: David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos Journal: Cancers (Basel) Date: 2020-05-15 Impact factor: 6.639
Authors: Julie Damgaard Sandahl; Eva A Coenen; Erik Forestier; Jochen Harbott; Bertil Johansson; Gitte Kerndrup; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Jean-Michel Cayuela; Lucy Chilton; Maarten Fornerod; Valérie de Haas; Christine J Harrison; Hiroto Inaba; Gertjan J L Kaspers; Der-Cherng Liang; Franco Locatelli; Riccardo Masetti; Christine Perot; Susana C Raimondi; Katarina Reinhardt; Daisuke Tomizawa; Nils von Neuhoff; Marco Zecca; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Henrik Hasle Journal: Haematologica Date: 2014-01-17 Impact factor: 9.941
Authors: F Locatelli; R Masetti; R Rondelli; M Zecca; F Fagioli; A Rovelli; C Messina; E Lanino; A Bertaina; C Favre; G Giorgiani; M Ripaldi; O Ziino; G Palumbo; M Pillon; A Pession; S Rutella; A Prete Journal: Bone Marrow Transplant Date: 2014-11-10 Impact factor: 5.483
Authors: Filip Matthijssens; Nitesh D Sharma; Monique Nysus; Christian K Nickl; Huining Kang; Dominique R Perez; Beatrice Lintermans; Wouter Van Loocke; Juliette Roels; Sofie Peirs; Lisa Demoen; Tim Pieters; Lindy Reunes; Tim Lammens; Barbara De Moerloose; Filip Van Nieuwerburgh; Dieter L Deforce; Laurence C Cheung; Rishi S Kotecha; Martijn Dp Risseeuw; Serge Van Calenbergh; Takeshi Takarada; Yukio Yoneda; Frederik W van Delft; Richard B Lock; Seth D Merkley; Alexandre Chigaev; Larry A Sklar; Charles G Mullighan; Mignon L Loh; Stuart S Winter; Stephen P Hunger; Steven Goossens; Eliseo F Castillo; Wojciech Ornatowski; Pieter Van Vlierberghe; Ksenia Matlawska-Wasowska Journal: J Clin Invest Date: 2021-03-15 Impact factor: 14.808
Authors: Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink Journal: Blood Date: 2011-05-06 Impact factor: 22.113
Authors: N S D Larmonie; T C J M Arentsen-Peters; A Obulkasim; D Valerio; E Sonneveld; A A Danen-van Oorschot; V de Haas; D Reinhardt; M Zimmermann; J Trka; A Baruchel; R Pieters; M M van den Heuvel-Eibrink; C M Zwaan; M Fornerod Journal: Oncogene Date: 2017-09-11 Impact factor: 9.867